Article info

Download PDFPDF

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Authors

  • Douglas B. Johnson Department of MedicineVanderbilt University Medical Center 777 PRB, 2220 Pierce Ave 37232 Nashville TN USA PubMed articlesGoogle scholar articles
  • Ali Manouchehri Department of MedicineVanderbilt University Medical Center 777 PRB, 2220 Pierce Ave 37232 Nashville TN USA PubMed articlesGoogle scholar articles
  • Alexandra M. Haugh Department of MedicineVanderbilt University Medical Center 777 PRB, 2220 Pierce Ave 37232 Nashville TN USA PubMed articlesGoogle scholar articles
  • Henry T. Quach Department of MedicineVanderbilt University Medical Center 777 PRB, 2220 Pierce Ave 37232 Nashville TN USA PubMed articlesGoogle scholar articles
  • Justin M. Balko Department of MedicineVanderbilt University Medical Center 777 PRB, 2220 Pierce Ave 37232 Nashville TN USA PubMed articlesGoogle scholar articles
  • Benedicte Lebrun-Vignes Department of PharmacologySorbonne Université, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital Paris France PubMed articlesGoogle scholar articles
  • Andrew Mammen Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Javid J. Moslehi Department of MedicineVanderbilt University Medical Center 777 PRB, 2220 Pierce Ave 37232 Nashville TN USA PubMed articlesGoogle scholar articles
  • Joe-Elie Salem Department of MedicineVanderbilt University Medical Center 777 PRB, 2220 Pierce Ave 37232 Nashville TN USA Department of PharmacologySorbonne Université, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital Paris France PubMed articlesGoogle scholar articles
  1. a Douglas.b.johnson{at}vumc.org
View Full Text

Citation

Johnson DB, Manouchehri A, Haugh AM, et al
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Publication history

  • Received March 11, 2019
  • Accepted May 13, 2019
  • First published May 22, 2019.
Online issue publication 
May 22, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.